Bacteria have lived in the presence of natural antibiotics and have evolved mechanisms to protect themselves. One such mechanism is the ability to form a biofilm – a ‘cling film’ like surface layer that prevents conventional antibiotics from reaching the bacteria. Furthermore the application of conventional antibiotics has been shown to stimulate the development of biofilm. Chronic infections typically have a biofilm component. A key feature of Matoke’s Reactive Oxygen® technology is that it has been shown to disrupt and prevent the production of biofilms.
The Reactive Oxygen® technology platform being developed by Matoke Holdings represents an exciting, innovative approach to the treatment of biofilm-associated infections. Very few treatments exist that specifically target biofilms, and it therefore offers a potential solution to a complex problem. The mechanism of action of this technology means it could either be utilised as an adjuvant therapy to improve antibiotic efficacy against tolerant biofilms, or as an alternative to conventionally prescribed antibiotics, thereby reducing the potential for the development of antibiotic resistance.
48 hour mature MRSA biofilm untreated.
Green is the presence of active biofilm.
Treated with 71g/L synthetic RO® for 24hours.
Red is destroyed biofilm.
Copyright © Matoke Holdings Limited | matokeholdings.com. All rights reserved.
Matoke Holdings Limited, Matoke Holdings Limited logo, Reactive Oxygen, Reactive Oxygen with atom logo, RO and RO with atom logo are all trademarks of Matoke Holdings Limited.
Web Design & Development by Eldo Web Design Ltd